Increased number of monocytes and plasma levels ofMCP‐1 andYKL‐40 in first‐episode psychosis

Authors:
  • KCKarolinska Schizophrenia Project (KaSP) Consortium
    Karolinska Schizophrenia Project (KaSP) Consortium

Abstract
Objective: Accumulating evidence implicates immune activation in the development of schizophrenia. Here, monocyte numbers, monocyte chemoattractant protein‐1 (MCP‐1) and chitinase‐3‐like protein 1 (YKL‐40) were investigated in plasma and cerebrospinal fluid (CSF) in first‐episode psychosis (FEP) patients.Method: CSFand blood were sampled from 42 first‐episode psychosis (FEP) patients and 22 healthy controls. The levels ofYKL‐40 andMCP‐1 were measured using electrochemiluminescence assay, and blood monocytes were counted using anXN‐9000‐hematology analyzer.Results: We found higher plasma levels ofMCP‐1 andYKL‐40 inFEPpatients compared with healthy controls, a condition that was unrelated to antipsychotic and/or anxiolytic medication. This was combined with an increased number of blood monocytes and a borderline significant increase inYKL‐40 levels in theCSFof tobacco‐freeFEPpatients. Plasma orCSFchemokines or blood monocytes did not correlate with the severity of symptoms or the level of functioning.Conclusion: These data demonstrate activation of monocytes inFEPand strengthens the idea of an immune dysfunction of psychotic disorders. Further studies are required to perceive a role ofYKL‐40 andMCP‐1 in the initiation and progression of schizophrenia.
Funding Information
  • Karolinska Institutet
  • Petrus och Augusta Hedlunds Stiftelse
  • Märta Lundqvists Stiftelse
  • Stiftelsen Professor Bror Gadelius Minnesfond
  • Stockholms Läns Landsting
  • Torsten Söderbergs Stiftelse
  • Knut och Alice Wallenbergs Stiftelse
  • Medicinska Forskningsrådet
  • Svenska Läkaresällskapet
  • Hjärnfonden

This publication has 48 references indexed in Scilit: